Immune signature of tumor infiltrating immune cells in renal cancer

OncoImmunology

Volumn 4, Issue 1, 2015, Pages 985082-

  Geissler, Katharina ^a   Fornara, Paolo ^a   Lautenschläger, Christine ^a   Holzhausen, Hans Jürgen ^a   Seliger, Barbara ^a   Riemann, Dagmar ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

CD13; CD57; CD69; flow cytometry; immunohistochemistry; immunophenotype; oncocytoma; renal cell carcinoma; survival; tumor infiltrating lymphocytes (TIL); tumor associated macrophages (TAM)

Indexed keywords

CD28 ANTIGEN; CD57 ANTIGEN; CD69 ANTIGEN; DIPEPTIDYL PEPTIDASE IV; HLA DR ANTIGEN; MICROSOMAL AMINOPEPTIDASE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELL VIABILITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; KIDNEY CARCINOMA; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; TUMOR DIFFERENTIATION;

EID: 84938723219     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/2162402X.2014.985082     Document Type: Article

References (40)

1. N.Kuroda, M.Toi, M.Hiroi, T.Shuin, H.Enzan. Review of renal oncocytoma with focus on clinical and pathobiological aspects. Histol Histopathol 2003; 18:935-42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12792905; PMID:12792905
2. E.Silverberg, J.Lubera. Cancer statistics. CA Cancer J Clin 1987; 37:2-19. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3099992; PMID:3099992; dx.doi.org/10.3322/canjclin.37.1.2
3. P.Russo. Renal cell carcinoma: presentation, staging, and surgical treatment. Semin Oncol 2000; 27:160-76. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10768595; PMID:10768595
4. R.J.Motzer, E.Basch. Targeted drugs for metastatic renal cell carcinoma. Lancet 2007; 370:2071-3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18156012; PMID:18156012; dx.doi.org/10.1016/S0140-6736(07)61874-1
5. T.L.Whiteside. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006; 16:3-15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16153857; PMID:16153857; dx.doi.org/10.1016/j.semcancer.2005.07.008
6. T.Shimabukuro, K.Naito. Tumor-infiltrating lymphocytes derived from human renal cell carcinoma: clonal analysis of its characteristics. Int J Urol 2008; 15:241-4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18304220; PMID:18304220; dx.doi.org/10.1111/j.1442-2042.2007.01977.x
7. J.Mautner, E.M.Jaffee, D.M.Pardoll. Tumor-specific CD4+ T cells from a patient with renal cell carcinoma recognize diverse shared antigens. Int J Cancer 2005; 115:752-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15704175; PMID:15704175; dx.doi.org/10.1002/ijc.20927
8. S.P.Sittig, T.Køllgaard, K.Grønbæk, M.Idorn, J.Hennenlotter, A.Stenzl, C.Gouttefangeas, P.Thor Straten. Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes. Oncoimmunology 2013; 2:e26014. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3820815&tool=pmcentrez&rendertype=abstract; PMID:24228230; dx.doi.org/10.4161/onci.26014
9. B.Frankenberger, E.Noessner, D.J.Schendel. Immune suppression in renal cell carcinoma. Semin Cancer Biol 2007; 17:330-43. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17656104; PMID:17656104; dx.doi.org/10.1016/j.semcancer.2007.06.004
10. W.S.Webster, C.M.Lohse, R.H.Thompson, H.Dong, X.Frigola, D.L.Dicks, S.Sengupta, I.Frank, B.C.Leibovich, M.L.Blute Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. Cancer 2006; 107:46-53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16708355; PMID:16708355; dx.doi.org/10.1002/cncr.21951
11. H.K.Jensen, F.Donskov, M.Nordsmark, N.Marcussen, H.von der Maase. Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma. Clin Cancer Res 2009; 15:1052-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19188179; PMID:19188179; dx.doi.org/10.1158/1078-0432.CCR-08-1296
12. Y.Komohara, H.Hasita, K.Ohnishi, Y.Fujiwara, S.Suzu, M.Eto, M.Takeya. Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci 2011; 102:1424-31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21453387; PMID:21453387; dx.doi.org/10.1111/j.1349-7006.2011.01945.x
13. D.Riemann, B.Göhring, J.Langner. Expression of aminopeptidase N/CD13 in tumour-infiltrating lymphocytes from human renal cell carcinoma. Immunol Lett 1994; 42:19-23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7829125; PMID:7829125; dx.doi.org/10.1016/0165-2478(94)90029-9
14. E.-J.Jung, H.J.Lee, C.Kwak, J.H.Ku, K.C.Moon. Young age is independent prognostic factor for cancer-specific survival of low-stage clear cell renal cell carcinoma. Urology 2009; 73:137-41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18950844; PMID:18950844; dx.doi.org/10.1016/j.urology.2008.08.460
15. M.Shabtai, H.Ye, Z.Frischer, J.Martin, W.C.Waltzer, K.Malinowski. Increased expression of activation markers in renal cell carcinoma infiltrating lymphocytes. J Urol 2002; 168:2216-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12394762; PMID:12394762; dx.doi.org/10.1016/S0022-5347(05)64358-3
16. L.E.Van den Hove, Van S.W.Gool, Van H.Poppel, L.Baert, L.Coorevits, B.Van Damme, J.L.Ceuppens. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma. Clin Exp Immunol 1997; 109:501-9. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1904758&tool=pmcentrez&rendertype=abstract; PMID:9328129; dx.doi.org/10.1046/j.1365-2249.1997.4771375.x
17. J.Bukur, V.Rebmann, H.Grosse-Wilde, H.Luboldt, H.Ruebben, I.Drexler, G.Sutter, C.Huber, B.Seliger. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res 2003; 63:4107-11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12874014; PMID:12874014
18. R.H.Thompson, H.Dong, E.D.Kwon. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res 2007; 13:709s-715s. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17255298; PMID:17255298; dx.doi.org/10.1158/1078-0432.CCR-06-1868
19. N.Rouas-Freiss, P.Moreau, J.LeMaoult, E.D.Carosella. The dual role of HLA-G in cancer. J Immunol Res 2014; 2014:359748. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3995100&tool=pmcentrez&rendertype=abstract; PMID:24800261; dx.doi.org/10.1155/2014/359748
20. J.Galon, H.K.Angell, D.Bedognetti, F.M.Marincola. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013; 39:11-26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23890060; PMID:23890060; dx.doi.org/10.1016/j.immuni.2013.07.008
21. N.A.Giraldo, E.Becht, R.Remark, D.Damotte, C.Sautès-Fridman, W.H.Fridman. The immune contexture of primary and metastatic human tumours. Curr Opin Immunol 2014; 27:8-15. Available from: http://www.sciencedirect.com/science/article/pii/S0952791514000028; PMID:24487185; dx.doi.org/10.1016/j.coi.2014.01.001
22. M.Ortmann, M.Vierbuchen, R.Fischer. Renal oncocytoma. II. Lectin and immunohistochemical features indicating an origin from the collecting duct. Virchows Arch B Cell Pathol Incl Mol Pathol [Internet] 1988 [cited 2013 Jun 28]; 56:175-84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2464870; PMID:2464870; dx.doi.org/10.1007/BF02890015
23. S.Störkel, R.Keymer, F.Steinbach, W.Thoenes. Reaction patterns of tumor infiltrating lymphocytes in different renal cell carcinomas and oncocytomas. Prog Clin Biol Res 1992; 378:217-23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1363795; PMID:1363795
24. Y.Han, Q.Guo, M.Zhang, Z.Chen, X.Cao. CD69+ CD4+ CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1. J Immunol 2009; 182:111-20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19109141; PMID:19109141; dx.doi.org/10.4049/jimmunol.182.1.111
25. E.Grage-Griebenow, E.Jerg, A.Gorys, D.Wicklein, D.Wesch, S.Freitag-Wolf, L.Goebel, I.Vogel, T.Becker, M.Ebsen L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression. Mol Oncol 2014; 8:982-97. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24746181; PMID:24746181; dx.doi.org/10.1016/j.molonc.2014.03.001
26. J.S.Schleypen, N.Baur, R.Kammerer, P.J.Nelson, K.Rohrmann, E.F.Gröne, M.Hohenfellner, A.Haferkamp, H.Pohla, D.J.Schendel Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res 2006; 12:718-25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16467081; PMID:16467081; dx.doi.org/10.1158/1078-0432.CCR-05-0857
27. D.Focosi, M.Bestagno, O.Burrone, M.Petrini. CD57+ T lymphocytes and functional immune deficiency. J Leukoc Biol 2010; 87:107-16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19880576; PMID:19880576; dx.doi.org/10.1189/jlb.0809566
28. P.K.Chattopadhyay, M.R.Betts, D.A.Price, E.Gostick, H.Horton, M.Roederer, S.C.De Rosa. The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. J Leukoc Biol [Internet] 2009; 85:88-97. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2638730&tool=pmcentrez&rendertype=abstract; PMID:18820174; dx.doi.org/10.1189/jlb.0208107
29. R.C.Wu, S.Liu, J.A.Chacon, S.Wu, Y.Li, P.Sukhumalchandra, J.L.Murray, J.J.Molldrem, P.Hwu, H.Pircher Detection and characterization of a novel subset of CD8+CD57+ T cells in metastatic melanoma with an incompletely differentiated phenotype. Clin Cancer Res 2012; 18:2465-77. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3343210&tool=pmcentrez&rendertype=abstract; PMID:22307139; dx.doi.org/10.1158/1078-0432.CCR-11-2034
30. Q.J.Wang, K.-I.Hanada, P.F.Robbins, Y.F.Li, J.C.Yang. Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma. Cancer Res 2012; 72:6119-29. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23071066; PMID:23071066; dx.doi.org/10.1158/0008-5472.CAN-12-0588
31. L.B.Jilaveanu, J.Sznol, S.A.Aziz, D.Duchen, H.M.Kluger, R.L.Camp. CD70 expression patterns in renal cell carcinoma. Hum Pathol 2012; 43:1394-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22401771; PMID:22401771; dx.doi.org/10.1016/j.humpath.2011.10.014
32. D.Riemann, K.Wenzel, T.Schulz, S.Hofmann, H.Neef, C.Lautenschläger, J.Langner. Phenotypic analysis of T lymphocytes isolated from non-small-cell lung cancer. Int Arch Allergy Immunol 1997; 114:38-45. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9303329; PMID:9303329; dx.doi.org/10.1159/000237640
33. D.Riemann, A.Kehlen, J.Langner. CD13–not just a marker in leukemia typing. Immunol Today 1999; 20:83-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10098327; PMID:10098327; dx.doi.org/10.1016/S0167-5699(98)01398-X
34. S.Ju, H.Qiu, X.Zhou, B.Zhu, X.Lv, X.Huang, J.Li, Y.Zhang, L.Liu, Y.Ge CD13 + CD4 + CD25 hi regulatory T cells exhibit higher suppressive function and increase with tumor stage in non-small cell lung cancer patients. Cell Cycle 2009; 8:2578-85; PMID:19597336; dx.doi.org/10.4161/cc.8.16.9302
35. Y.Komohara, M.Jinushi, M.Takeya. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci 2014; 105:1-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24168081; PMID:24168081; dx.doi.org/10.1111/cas.12314
36. A.C.Ochoa, A.H.Zea, C.Hernandez, P.C.Rodriguez. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007; 13:721s-6s. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17255300; PMID:17255300; dx.doi.org/10.1158/1078-0432.CCR-06-2197
37. S.R.Dannenmann, J.Thielicke, M.Stöckli, C.Matter, L.von Boehmer, V.Cecconi, T.Hermanns, L.Hefermehl, P.Schraml, H.Moch Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. Oncoimmunology 2013; 2:e23562. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3655740&tool=pmcentrez&rendertype=abstract; PMID:23687622; dx.doi.org/10.4161/onci.23562
38. L.Xu, Y.Zhu, L.Chen, H.An, W.Zhang, G.Wang, Z.Lin, J.Xu. Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma. Ann Surg Oncol 2014; 21(9):3142-50; PMID: 24615178; dx.doi.org/10.1245/s10434-014-3601-1
39. S.Hase, K.Weinitschke, K.Fischer, P.Fornara, R.Hoda, S.Unverzagt, B.Seliger, D.Riemann. Monitoring peri-operative immune suppression in renal cancer patients. Oncol Rep 2011; 25:1455-64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21369703; PMID:21369703
40. R.R.Laborde, Y.Lin, M.P.Gustafson, P.A.Bulur, A.B.Dietz. Cancer vaccines in the world of immune suppressive monocytes (CD14(+)HLA-DR(lo/neg) cells): the gateway to improved responses. Front Immunol 2014; 5:147. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3983500&tool=pmcentrez&rendertype=abstract; PMID:24772111; dx.doi.org/10.3389/fimmu.2014.00147